Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer
CPT: Pharmacometrics & Systems Pharmacology · 2024
DOI: 10.1002/psp4.13155 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Peng Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Department, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Antibodies, Monoclonal, Humanized, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Adebrelimab, a novel anti‐PD‐L1 antibody, has been approved by the National Medical Products Administration of China as an intravenous infusion for use in combination with carboplatin and etoposide as first‐line treatment for extensive‐stage small‐cell lung cancer in 2023. A two‐compartment model with empirical time‐varying CL for adebrelimab was established based on data from 263 patients receiving body weight‐based doses from two clinical studies. Significant covariate effects of baseline body weight, albumin levels, tumor size, neutrophil counts, and presence of anti‐drug antibodies were identified on CL of debrelimab, none of which were clinically significant or warranted dose adjustment. The degree of decrease in CL was higher in patients who responded to treatment with adebrelimab than in non‐responders. Adebrelimab exposures (AUC, C trough , or C max ) were not identified as a statistically significant factor related to efficacy or safety endpoint in the exposure–response analysis. Distribution of simulated exposure metrics from the flat dose regimen (1200 mg q3w) was similar to the marketed weight‐based dosing regimen (20 mg/kg q3w), supporting the alternative flat dose regimen in the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Department, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
- Oncology Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
- Clinical Pharmacology Department, Luzsana Biotechnology/Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
ORCID-Profile: Nassim Djebli
Zitieren
APA
Chen, P., Zhang, Y., Wang, Y., Ma, K., Shi, W., Djebli, N., & Shen, K. (2024). Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13155
Vancouver
Chen P, Zhang Y, Wang Y, Ma K, Shi W, Djebli N, et al. Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13155
BibTeX
@article{Chen2024,
author = {Chen, Peng and Zhang, Yanyan and Wang, Yike and Ma, Ke and Shi, Wei and Djebli, Nassim and Shen, Kai},
title = {Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2024},
doi = {10.1002/psp4.13155}
}
EUVIMED